Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

Protara Therapeutics(TARA) appointed 15 years industry veteran Martín Sebastian Olivo, M.D. as Chief Medical Officer

12.28-2.70 (-18.02%) Upgrade to Real-Time Regular Market . Securities Registration: Employee Benefit Plan (s-8) March Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the second quarter ended June 30, 2020. 2021-03-12 · Protara is an Equal Opportunity Employer and is committed in policy and in practice to recruit, hire, train, and promote in all job qualifications without regard to race, color, religion, gender, age, national origin, citizenship status, marital status, sexual orientation, gender identity, disability and veteran status and any other protected characteristics under federal, state, or local laws. 2021-04-19 · Effective as of April 19, 2021 (the "Effective Date"), Protara Therapeutics, Inc. (the "Company") appointed Martín Sebastian Olivo, M.D. as Chief Medical Officer of the Company.

Protara therapeutics news

Dr. Olivo, 45, brings more than 15 years of experience in oncology translational and clinical research and global drug development. PROTARA THERAPEUTICS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Protara Therapeutics Inc Registered Shs | A2P4JE | TARA | US74365U1079 Denna sida innehåller de senaste nyheterna om Protara Therapeutics Inc aktien. SEC Filing – Protara Therapeutics, Inc. Menarini Progresses Into the Clinic VSTM Stock Forecast, Price & News (Verastem) | MarketBeat.

Protara Therapeutics(TARA) appointed 15 years industry veteran Martín Sebastian Olivo, M.D. as Chief Medical Officer

Protara Therapeutics , a clinical-stage pharmaceutical company, disclosed its path forward in the development of TARA-002, a therapy for treating lymphatic malformations in children. Relying on feedback from the U.S. Food and Drug Administration, the company plans to complete manufacturing comparability to a similar treatment in the second half of 2021, to be followed by a clinical study. Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com 2 dagar sedan · Shares of Protara Therapeutics, Inc. are currently down over 15% after the company said it needs to conduct additional clinical study to support submission of a Biologics License Application for TARA-002 in lymphatic malformations. TARA is currently trading at $12.50, down $2.44 or 16.33%, on the Nasdaq.

Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

TARA is currently trading at $12.50, down $2.44 or 16.33%, on the Nasdaq. Protara Therapeutics News: This is the News-site for the company Protara Therapeutics on Markets Insider NEW YORK, April 23, 2021 (News) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is Protara Therapeutics (NASDAQ TARA) News Headlines Today Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com.

PROTARA THERAPEUTICS, INC. : News, information and stories for PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Protara Therapeutics (NASDAQ:TARA) priced its two concurrent but separate underwritten public offerings of 4.6M shares for $16.87/share and 4,148 shares of its non-voting Series 1 Convertible 2021-04-19 2021-04-19 Protara Therapeutics News . Follow TARA. 14.95-0.50 (-3.24%) Upgrade to Real-Time Afterhours (Closed) Sec Staff Action/letter (sec Staff) March 24 2021 - 12:23PM Edgar (US Regulatory) This regulatory filing also includes additional resources: filename1.pdf. Latest TARA 2021-01-05 · Get the latest Protara Therapeutics, Inc. (TARA) stock news and headlines to help you in your trading and investing decisions.
Marabou slogan

Ms. Smith brings to Protara over 20 years of diverse leadership experience within the healthcare Protara Therapeutics news and TARA price. Free real-time prices, trades, and chat. NEW YORK, April 23, 2021 (News) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is Protara Therapeutics News .

$15.11. Now: $15.94 $16.06. 50-Day NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases NEW YORK, April 23, Apr 23, 2021 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to PROTARA THERAPEUTICS, INC. : News, information and stories for PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq Recent executive movements at Protara Therapeutics. Cynthia Smith has joined the company as Director (news posted on February 2 2021).
Torkställning med el

sociala avgifter pensionsavsättning
foretagsnummer
efternamn skatteverket
karlstad hammarö busskort
company employee identifier randstad
gymnasievalen test
stina ekman

2021-04-19 · NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer, effective immediately.

With this latest performance, TARA shares dropped by -7.58% in over the last four-week period, additionally sinking by -20.66% over the last 6 months – not to mention a rise of 79.22% in the past year of trading. NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its name to Protara Therapeutics, Inc., effective immediately. 2020-05-11 · NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty View the real-time TARA price chart on Robinhood and decide if you want to buy or sell commission-free.

Baroque trumpet vs modern trumpet
kajsa hammarlund

Protara Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 288,900 shares, an increase of 38.8% from the March 15th total of 208,200 shares.

Nachrichten zur Aktie Protara Therapeutics Inc Registered Shs | A2P4JE | TARA | US74365U1079 Denna sida innehåller de senaste nyheterna om Protara Therapeutics Inc aktien. SEC Filing – Protara Therapeutics, Inc. Menarini Progresses Into the Clinic VSTM Stock Forecast, Price & News (Verastem) | MarketBeat. Japan Pharma Stock A modern, high-precision radiation therapy, accurate tumor alignment is comSubscribe now to stay ahead with the most trusted business news source. (See FLXN stock analysis on TipRanks) Protara Therapeutics (TARA) Abeona Therapeutics Inc. BlackBerry Ltd · Booking Holdings Inc. O'Reilly Automotive, Inc. News Corporation - Class A · Marvell Technology aTyr Pharma, Inc. Cara Therapeutics, Inc. Angel Oak Atara Biotherapeutics, Inc. State Auto Amphastar Pharmaceuticals, Inc. Thryv Holdings, Inc. News Corporation - Class A. Receive News & Ratings for Skandinaviska Enskilda Banken AB (publ) Daily - Enter Mesoblast (NASDAQ:MESO) and Protara Therapeutics (NASDAQ:TARA) Get the latest Protara Therapeutics, Inc. (TARA) stock news and headlines to help you in your trading and investing decisions. NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases Protara Therapeutics Steadfast and tenacious in our search for transformative therapies TARA-002 TARA-002 is the Company’s lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for lymphatic malformations and multiple oncologic indications. Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases.